Cited by 1,649Epigenetics and DNA MethylationCancer Cells and MetastasisMechanisms of cancer metastasis

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Open access

Kleer, Celina G., Cao, Qi, Varambally, Sooryanarayana, Shen, Ronglai, Ota, Ichiro, Tomlins, Scott A., Ghosh, Debashis, Sewalt, Richard G. A. B., Otte, Arie P., Hayes, Daniel F., Sabel, Michael S., Livant, Donna, Weiss, Stephen J., Rubin, Mark A., Chinnaiyan, Arul M.·2003·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1933744100PMC PMC208805

Open this paper in CoChat — free account

Abstract

The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer. Here we investigate the functional role of EZH2 in cancer cell invasion and breast cancer progression. EZH2 transcript and protein were consistently elevated in invasive breast carcinoma compared with normal breast epithelia. Tissue microarray analysis, which included 917 samples from 280 patients, demonstrated that EZH2 protein levels were strongly associated with breast cancer aggressiveness. Overexpression of EZH2 in immortalized human mammary epithelial cell lines promotes anchorage-independent growth and cell invasion. EZH2-mediated cell invasion required an intact SET domain and histone deacetylase activity. This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1933744100

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Ki67 expression in breast cancer
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Cancer Statistics, 2003
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Self-citation
Diseases of the Breast
Haagenson, C. (1971) · Cited by 1,773

Flagged first, then by citations

Show all 38 references

1 of the 38 references couldn’t be matched to a known paper.

Research works printed but not linked: 7

Ellis M. Hayes D. & Lippman M. (2000) in Diseases of the Breast eds. Harris J. Lippman M. E. & Morrow M. (Lippincott–Raven Philadelpha) pp. 749–798.
Clark G. M. (1996) in Diseases of the Breast eds. Harris. J. L. M.. Morrow M. & Hellman S. (Lippincott–Raven Philadephia) pp. 461–485.
Tie, F., Furuyama, T., Prasad-Sinha, J., Jane, E. & Harte, P. J. (2001) Development (Cambridge, U.K.) 128, 275–286.
Livant, D. L., Linn, S., Markwart, S. & Shuster, J. (1995) Cancer Res. 55, 5085–5093.7585556
Rhodes, D. R., Barrette, T. R., Rubin, M. A., Ghosh, D. & Chinnaiyan, A. M. (2002) Cancer Res. 62, 4427–4433.12154050
Gruvberger, S., Ringner, M., Chen, Y., Panavally, S., Saal, L. H., Borg, A., Ferno, M., Peterson, C. & Meltzer, P. S. (2001) Cancer Res. 61, 5979–5984.11507038
Livant, D. L., Brabec, R. K., Pienta, K. J., Allen, D. L., Kurachi, K., Markwart, S. & Upadhyaya, A. (2000) Cancer Res. 60, 309–320.10667582

Sorted by citations

Items 501–600 of 1,000

Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo
Chang, Y., Ding, B., Zhang, X., Deng, X., Deng, K., Cheng, Z., Xing, B., Jin, D., Ma, P., & Lin, J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.014 · Cited by 76
Tumorigenic Cell Reprogramming and Cancer Plasticity: Interplay between Signaling, Microenvironment, and Epigenetics
Poli, V., Fagnocchi, L., & Zippo, A. (2018) · Stem Cells International · doi:10.1155/2018/4598195 · Cited by 81
Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression
Vantaku, V., Putluri, V., Bader, D. A., Maity, S., Ma, J., Arnold, J. M., Rajapakshe, K., Donepudi, S. R., von Rundstedt, F.-C., Devarakonda, V., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0902-7 · Cited by 76
Self-citation
FOXP3 Orchestrates H4K16 Acetylation and H3K4 Trimethylation for Activation of Multiple Genes by Recruiting MOF and Causing Displacement of PLU-1
Katoh, H., Qin, Z. S., Liu, R., Wang, L., Li, W., Li, X., Wu, L., Du, Z., Lyons, R., Liu, C., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.10.012 · Cited by 74
The emerging role of miRNA clusters in breast cancer progression
Kandettu, A., Radhakrishnan, R. A., Chakrabarty, S., Sriharikrishnaa, S., & Kabekkodu, S. P. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188413 · Cited by 74
Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements
Tonini, T., D’Andrilli, G., Fucito, A., Gaspa, L., & Bagella, L. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21241 · Cited by 75
Mechanisms of Yin Yang 1 in Oncogenesis: The Importance of Indirect Effects
Atchison, M. L., Basu, A., Zápražná, K., & Papasani, M. R. (2011) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v16.i3-4.20 · Cited by 74
Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancerThis paper is one of a selection of papers published in this Special Issue, entitled The 30th Annual International Asilomar Chromatin and Chromosomes Conference, and has undergone the Journal's usual peer review process.
Gieni, R. S., & Hendzel, M. J. (2009) · Biochemistry and Cell Biology · doi:10.1139/o09-057 · Cited by 76
Chromatin remodeling in Embryonic stem cells: Regulating the balance between pluripotency and differentiation
Keenen, B., & de la Serna, I. L. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21654 · Cited by 76
Epigenetic Factors in Cancer Development: Polycomb Group Proteins
Piunti, A., & Pasini, D. (2010) · Future Oncology · doi:10.2217/fon.10.157 · Cited by 76
Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer
Friel, A. M., Corcoran, C., Crown, J. P., & O’Driscoll, L. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0980-2 · Cited by 75
Targeting Histone Methylation in Cancer
McCabe, M. T., Mohammad, H. P., Barbash, O., & Kruger, R. G. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000283 · Cited by 76
Corepressors of agonist-bound nuclear receptors
Gurevich, I., Flores, A. M., & Aneskievich, B. J. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.05.019 · Cited by 73
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
Schade, A. E., Perurena, N., Yang, Y., Rodriguez, C. L., Krishnan, A., Gardner, A., Loi, P., Xu, Y., Nguyen, V. T. M., Mastellone, G. M., et al. (2024) · Nature · doi:10.1038/s41586-024-08031-6 · Cited by 72
A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard
Won, J., Gao, D., Chow, C., Cheng, J., Lau, S., Ellis, M. J., Perou, C. M., Bernard, P. S., & Nielsen, T. O. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.97 · Cited by 72
Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases
Mimori, K., Ogawa, K., Okamoto, M., Sudo, T., Inoue, H., & Mori, M. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2004.11.001 · Cited by 73
The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells
Wagener, N., Holland, D., Bulkescher, J., Crnković‐Mertens, I., Hoppe‐Seyler, K., Zentgraf, H., Pritsch, M., Buse, S., Pfitzenmaier, J., Haferkamp, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23683 · Cited by 74
Telomerase reverse transcriptase (TERT) ‐ enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and DNA damage responses in glioblastoma
Ahmad, F., Patrick, S., Sheikh, T., Sharma, V., Pathak, P., Malgulwar, P. B., Kumar, A., Joshi, S. D., Sarkar, C., & Sen, E. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14152 · Cited by 73
EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development
Kunju, L. P., Cookingham, C., Toy, K. A., Chen, W., Sabel, M. S., & Kleer, C. G. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.8 · Cited by 73
Self-citation
The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma
Liu, M., Scanlon, C. S., Banerjee, R., Russo, N., Inglehart, R. C., Willis, A. L., Weiss, S. J., & D’Silva, N. J. (2013) · Translational Oncology · doi:10.1593/tlo.13175 · Cited by 71
Self-citation
CCN6 Modulates BMP Signaling via the Smad-Independent TAK1/p38 Pathway, Acting to Suppress Metastasis of Breast Cancer
Pal, A., Huang, W., Li, X., Toy, K. A., Nikolovska‐Coleska, Z., & Kleer, C. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0154 · Cited by 70
Self-citation
Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis
Tao, T., Chen, M., Jiang, R., Guan, H., Huang, Y., Su, H., Hu, Q., Han, X., & Xiao, J. (2017) · Oncology Reports · doi:10.3892/or.2017.5430 · Cited by 70
MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells
Rajabi, H. N., Hiraki, M., & Kufe, D. W. (2018) · Oncogene · doi:10.1038/s41388-017-0096-9 · Cited by 71
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
Jansen, M. P. H. M., Reijm, E. A., Sieuwerts, A. M., Ruigrok-Ritstier, K., Look, M. P., Rodríguez-González, F. G., Heine, A. A. J., Martens, J. W. M., Sleijfer, S., Foekens, J. A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1877-4 · Cited by 70
Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation
Kwon, H., Song, K., Han, C., Zhang, J., Lu, L., Chen, W., & Wu, T. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.06.014 · Cited by 71
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A
Tonini, T., Bagella, L., D’Andrilli, G., Claudio, P. P., & Giordano, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207608 · Cited by 72
Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer
Tamagawa, H., Oshima, T., Numata, M., Yamamoto, N., Shiozawa, M., Morinaga, S., Nakamura, Y., Yoshihara, M., Sakuma, Y., Kameda, Y., et al. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.02.023 · Cited by 70
Loss of Estrogen Receptor 1 Enhances Cervical Cancer Invasion
Zhai, Y., Bommer, G. T., Feng, Y., Wiese, A. B., Fearon, E. R., & Cho, K. R. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091166 · Cited by 70
Curcumin inhibits the growth of triple‐negative breast cancer cells by silencing EZH2 and restoring DLC1 expression
Zhou, X., Jiao, D., Dou, M., Zhang, W., Lv, L., Chen, J., Li, L., Wang, L., & Han, X. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15683 · Cited by 71
CRISPR/Cas9-Mediated Genome Editing of Epigenetic Factors for Cancer Therapy
Yao, S., He, Z., & Chen, C. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.067 · Cited by 70
Lysine methylation of promoter-bound transcription factors and relevance to cancer
Stark, G. R., Wang, Y., & Lu, T. (2010) · Cell Research · doi:10.1038/cr.2010.174 · Cited by 69
Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis
Jiang, T., Wang, Y., Zhou, F., Gao, G., Ren, S., & Zhou, C. (2015) · Oncotarget · doi:10.18632/oncotarget.6612 · Cited by 68
Combined inhibition of EZH 2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells
Takashina, T., Kinoshita, I., Kikuchi, J., Shimizu, Y., Sakakibara‐Konishi, J., Oizumi, S., Nishimura, M., & Dosaka‐Akita, H. (2016) · Cancer Science · doi:10.1111/cas.12957 · Cited by 70
3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression
Ni, J., Hou, X., Wang, X., Shi, Y., Xu, L., Zheng, X., Liu, N., Qiu, A., & Zhuang, S. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1589-y · Cited by 69
EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial–Mesenchymal Transition and anoikis in colon cancer cells
Ferraro, A., Mourtzoukou, D., Kosmidou, V., Avlonitis, S., Kontogeorgos, G., Zografos, G., & Pintzas, A. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.10.009 · Cited by 69
Dysregulated Expression of Stem Cell Factor Bmi1 in Precancerous Lesions of the Gastrointestinal Tract
Tateishi, K., Ohta, M., Kanai, F., Guleng, B., Tanaka, Y., Asaoka, Y., Tada, M., Seto, M., Jazag, A., Lianjie, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0449 · Cited by 67
EZH2 in Bladder Cancer, a Promising Therapeutic Target
Martínez‐Fernández, M., Rubio, C., Segovia, C., López-Calderón, F., Dueñas, M., & Paramio, J. M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126000 · Cited by 68
Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell Line
Karanikolas, B. D. W., Figueiredo, M. L., & Wu, L. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0121 · Cited by 68
H3K27 Methylation
Nichol, J. N., Dupéré-Richer, D., Ezponda, T., Licht, J. D., & Miller, W. H. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.001 · Cited by 75
The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis
Ma, X., Wang, J., Wang, J., Charles, X., Gao, X., Patriub, V., & Sklar, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13270 · Cited by 70
Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer
Oki, S., Sone, K., Oda, K., Hamamoto, R., Ikemura, M., Maeda, D., Takeuchi, M., Tanikawa, M., Mori‐Uchino, M., Nagasaka, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16316 · Cited by 68
UTX promotes hormonally responsive breast carcinogenesis through feed-forward transcription regulation with estrogen receptor
Xie, G., Liu, X., Zhang, Y., Li, W., Liu, S., Chen, Z., Xu, B., Yang, J.-Y., He, L., Zhang, Z., et al. (2017) · Oncogene · doi:10.1038/onc.2017.157 · Cited by 67
ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors
Rehman, H., Chandrashekar, D. S., Balabhadrapatruni, C., Nepal, S., Balasubramanya, S. A. H., Shelton, A., Skinner, K., Ma, A., Rao, T., Agarwal, S., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155899 · Cited by 67
Self-citation
EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo
Guo, J., Cai, J., Yu, L., Tang, H., Chen, C., & Wang, Z. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01836.x · Cited by 68
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma
Toll, A. D., Dasgupta, A., Potoczek, M., Yeo, C. J., Kleer, C. G., Brody, J. R., & Witkiewicz, A. K. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.03.004 · Cited by 67
Self-citation
Epigenetic transcriptional repression of cellular genes by a viral SET protein
Mujtaba, S., Manzur, K. L., Gurnon, J. R., Kang, M., Etten, J. L. V., & Zhou, M. (2008) · Nature Cell Biology · doi:10.1038/ncb1772 · Cited by 66
Enhancer of Zeste Homolog 2 (EZH2) Promotes Progression of Cholangiocarcinoma Cells by Regulating Cell Cycle and Apoptosis
Nakagawa, S., Okabe, H., Sakamoto, Y., Hayashi, H., Hashimoto, D., Yokoyama, N., Sakamoto, K., Kuroki, H., Mima, K., Nitta, H., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3135-y · Cited by 67
Sulforaphane Suppresses Polycomb Group Protein Level via a Proteasome-Dependent Mechanism in Skin Cancer Cells
Balasubramanian, S., Chew, Y. C., & Eckert, R. L. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072363 · Cited by 66
EZH2 Represses Target Genes through H3K27-Dependent and H3K27-Independent Mechanisms in Hepatocellular Carcinoma
Gao, S.-B., Zheng, Q., Xu, B., Pan, C.-B., Li, K., Zhao, Y., Zheng, Q., Lin, X., Xue, L., & Jin, G. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0034 · Cited by 67
Diffusible signals and epigenetic timing cooperate in late proximo-distal limb patterning
Roselló‐Díez, A., Arqués, C. G., Delgado, I., Giovinazzo, G., & Torres, M. (2014) · Development · doi:10.1242/dev.106831 · Cited by 66
EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma
Chen, Q., Zheng, P., & Yang, W. (2016) · Oncotarget · doi:10.18632/oncotarget.8741 · Cited by 65
The EZH2–PHACTR2–AS1–Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer
Chu, W., Zhang, X., Qi, L., Fu, Y., Wang, P., Zhao, W., Du, J., Zhang, J., Zhan, J., Wang, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3326 · Cited by 66
Discovery, design, and synthesis of indole-based EZH2 inhibitors
Gehling, V. S., Vaswani, R. G., Nasveschuk, C. G., Duplessis, M., Iyer, P., Balasubramanian, S., Zhao, F., Good, A. C., Campbell, R., Lee, C., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.06.056 · Cited by 67
Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability
Wen, W., Peng, C., Kim, M., Jeong, C. H., Zhu, F., Yao, K., Zykova, T. A., Ma, W., Carper, A., Langfald, A., et al. (2013) · Oncogene · doi:10.1038/onc.2012.605 · Cited by 66
Polycomb proteins in mammalian cell differentiation and plasticity
Prezioso, C., & Orlando, V. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.062 · Cited by 67
Targeting protein lysine methylation and demethylation in cancers
He, Y., Korboukh, I., Jin, J. J., & Huang, J. L. (2011) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmr109 · Cited by 68
Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome
Gong, Y. Y., Huo, L., Liu, P., Sneige, N., Sun, X., Ueno, N. T., Lucci, A., Buchholz, T. A., Valero, V., & Cristofanilli, M. (2011) · Cancer · doi:10.1002/cncr.26179 · Cited by 66
Structure–Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors
Yang, X., Li, F., Konze, K. D., Meslamani, J. E., Ma, A., Brown, P. J., Zhou, M., Arrowsmith, C. H., Kanıskan, H. Ü., Vedadi, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00855 · Cited by 65
Dysregulation of histone methyltransferases in breast cancer – Opportunities for new targeted therapies?
Michalak, E. M., & Visvader, J. E. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.003 · Cited by 69
INTEGRATIVE BIOLOGY OF PROSTATE CANCER PROGRESSION
Tomlins, S. A., Rubin, M. A., & Chinnaiyan, A. M. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100047 · Cited by 66
Self-citation
Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells
Zhao, J., Jin, W., Yi, K., Wang, Q., Zhou, J., Tan, Y., Xu, C., Xiao, M., Hong, B., Xu, F., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105764 · Cited by 65
Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression
Alford, S. H., Toy, K. A., Merajver, S. D., & Kleer, C. G. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1591-2 · Cited by 66
Self-citation
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers
Au, S. L., Wong, C. C., Lee, J. M., Wong, C., & Ng, I. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068226 · Cited by 67
Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer
Song, X., Gao, T., Wang, N., Feng, Q., You, X., Ye, T., Lei, Q., Zhu, Y., Xiong, M., Xia, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep20864 · Cited by 65
Quercetin‑3‑methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways
Cao, L., Yang, Y., Ye, Z., Lin, B., Zeng, J., Li, C., Liang, T., Zhou, K., & Li, J. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3741 · Cited by 64
Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer
Yu, Y., Qi, J., Xiong, J., Jiang, L., Cui, D., He, J., Chen, P., Li, L., Wu, C., Ma, T., et al. (2019) · Theranostics · doi:10.7150/thno.29520 · Cited by 66
EZH2-mediated development of therapeutic resistance in cancer
Kaur, P., Shankar, E., & Gupta, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216706 · Cited by 64
Inhibition of CCN6 (Wnt-1-Induced Signaling Protein 3) Down-Regulates E-Cadherin in the Breast Epithelium through Induction of Snail and ZEB1
Huang, W., Zhang, Y., Varambally, S., Chinnaiyan, A. M., Banerjee, M., Merajver, S. D., & Kleer, C. G. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070899 · Cited by 63
Self-citation
RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo
Chen, Y., Xie, D., Li, W. Y., Cheung, C. M., Yao, H., Chan, C. Y., Chan, C., Xu, F.-P., Liu, Y. H., Sung, J. J. �., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.05.003 · Cited by 66
Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2
Nasveschuk, C. G., Gagnon, A., Garapaty, S., Balasubramanian, S., Campbell, R., Lee, C., Zhao, F., Bergeron, L., Cummings, R. T., Trojer, P., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400494b · Cited by 63
The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER‐positive breast cancers
Bae, W. K., Yoo, K. H., Lee, J. S., Kim, Y., Chung, I., Park, M. H., Yoon, J. H., Furth, P. A., & Hennighausen, L. G. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22188 · Cited by 66
Targeting EZH2 for Cancer Therapy: Progress and Perspective
Li, C. H., & Chen, Y. (2015) · Current Protein and Peptide Science · doi:10.2174/1389203716666150409100233 · Cited by 63
Metformin as an adjuvant in breast cancer treatment
Roshan, M. H. K., Shing, Y. K., & Pace, N. P. (2019) · SAGE Open Medicine · doi:10.1177/2050312119865114 · Cited by 63
Role of H3K27 Demethylases Jmjd3 and UTX in Transcriptional RegulationPreprint
Hübner, M. R., & Spector, D. L. (2010) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2010.75.020 · Cited by 65
Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma
Qamra, A., Xing, M., Padmanabhan, N., Kwok, J. J. T., Zhang, S., Xu, C., Leong, Y. S., Lim, A. P. L., Tang, Q., Ooi, W. F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1022 · Cited by 64
Chemical Probes of Histone Lysine Methyltransferases
Kanıskan, H. Ü., & Jin, J. J. (2014) · ACS Chemical Biology · doi:10.1021/cb500785t · Cited by 63
NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2
Donatis, G. M. D., Pape, E. L., Pierron, A., Chéli, Y., Hofman, V., Hofman, P. M., Allegra, M., Zahaf, K., Bahadoran, P., Rocchi, S., et al. (2015) · Oncogene · doi:10.1038/onc.2015.331 · Cited by 67
The Multiple Facets of PRC2 Alterations in Cancers
Wassef, M. A., & Margueron, R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.012 · Cited by 72
Enhancer of Zeste 2 as a Marker of Preneoplastic Progression in the Breast
Ding, L., & Kleer, C. G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2384 · Cited by 62
Self-citation
The JARID2–PRC2 duality: Figure 1.Preprint
Herz, H., & Shilatifard, A. (2010) · Genes & Development · doi:10.1101/gad.1921610 · Cited by 64
Targeting the epigenome for treatment of cancer
Geutjes, E.-J., Bajpe, P. K., & Bernards, R. (2011) · Oncogene · doi:10.1038/onc.2011.552 · Cited by 62
Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus
Ochiai (2010) · International Journal of Oncology · doi:10.3892/ijo.2010.868 · Cited by 62
EZH2 Regulates Cofilin Activity and Colon Cancer Cell Migration by Targeting ITGA2 Gene
Ferraro, A., Boni, T., & Pintzas, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115276 · Cited by 61
Development and Validation of Reagents and Assays for EZH2 Peptide and Nucleosome High-Throughput Screens
Diaz, E., Machutta, C. A., Chen, S., Jiang, Y., Nixon, C., Hofmann, G. A., Key, D. E., Sweitzer, S. M., Patel, M. P., Wu, Z., et al. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112453765 · Cited by 63
Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma
Williams, M. J., Singleton, W., Lowis, S. P., Malik, K. T. A., & Kurian, K. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00045 · Cited by 62
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer
Zhang, P., Xiao, Z., Wang, S., Zhang, M., Wei, Y., Hang, Q., Kim, J., Yao, F., Rodriguez‐Aguayo, C., Ton, B. N., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.078 · Cited by 62
Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges
Chen, Y., Liu, X., Li, Y., Quan, C., Zheng, L., & Huang, K. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.06.001 · Cited by 62
An RNA matchmaker protein regulates the activity of the long noncoding RNA HOTAIR
Meredith, E. K., Balas, M. M., Sindy, K., Haislop, K. S., & Johnson, A. M. (2016) · RNA · doi:10.1261/rna.055830.115 · Cited by 62
Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
Sun, R., Shen, J. K., Gao, Y., Zhou, Y., Yu, Z., Hornicek, F. J., Kan, Q., & Duan, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.9518 · Cited by 63
Role of HOTAIR in the diagnosis and prognosis of acute leukemia
Zhang, Y., Huang, S., Zhou, H., Chen, C., Tian, L.-H., & Shen, J. (2016) · Oncology Reports · doi:10.3892/or.2016.5147 · Cited by 61
Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2
Christofides, A., Karantanos, T., Bardhan, K., & Boussiotis, V. A. (2016) · Oncotarget · doi:10.18632/oncotarget.12928 · Cited by 61
RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer
Tarcic, O., Granit, R. Z., Pateras, I. S., Masury, H., Maly, B., Zwang, Y., Yarden, Y., Gorgoulis, V. G., Pikarsky, E., Ben‐Porath, I., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2016.126 · Cited by 60
Pathologic Features of Breast Cancer Associated With Complete Response to Neoadjuvant Chemotherapy
Pu, R. T., Schott, A. F., Sturtz, D. E., Griffith, K. A., & Kleer, C. G. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000152138.89395.fb · Cited by 60
Self-citation
MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21waf1/cip1
Semaan, A. Y., Qazi, A. M., Seward, S. M., Chamala, S., Bryant, C. S., Kumar, S., Morris, R. T., Steffes, C. P., Bouwman, D. L., Munkarah, A. R., et al. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0547-x · Cited by 59
Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma
Yamaguchi, J., Sasaki, M., Sato, Y., Itatsu, K., Harada, K., Zen, Y., Ikeda, H., Nimura, Y., Nagino, M., & Nakanuma, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01387.x · Cited by 60
S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells
Liu, T., Lo, H.-L., Wei, L.-S., Hsiao, H. H.-Y., & Yang, P. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000166 · Cited by 59
Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2
Huang, W.-Y., Yang, P., Chang, Y.-F., Márquez, V. E., & Chen, C. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.11.014 · Cited by 62
Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses’ Health Study
Healey, M. A., Hu, R., Beck, A. H., Collins, L. C., Schnitt, S. J., Tamimi, R. M., & Hazra, A. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3089-1 · Cited by 59
Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma
Yonemitsu, Y., Imazeki, F., Chiba, T., Fukai, K., Nagai, Y., Miyagi, S., Arai, M., Aoki, R., Miyazaki, M., Nakatani, Y., et al. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.01.017 · Cited by 59

Authors: Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., Sabel, M. S., Livant, D., Weiss, S. J., Rubin, M. A., & Chinnaiyan, A. M.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Kleer, Celina G.
Cao, Qi
Varambally, Sooryanarayana
Shen, Ronglai
Ota, Ichiro
Tomlins, Scott A.
Hayes, Daniel F.
Sabel, Michael S.
Weiss, Stephen J.
Rubin, Mark A.
Chinnaiyan, Arul M.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2003-09-19
Volume: 100
Issue: 20
Pages: 11606-11611
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1933744100
PMC: PMC208805
OpenAlex: W2100365251
Cited by: 1,649
References: 38
Citations by year: 2026: 21 · 2025: 43 · 2024: 53 · 2023: 72 · 2022: 55 · 2021: 67 · 2020: 94 · 2019: 69 · 2018: 83 · 2017: 91 · 2016: 109 · 2015: 109 · 2014: 116 · 2013: 114 · 2012: 108
FWCI: 12.78
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UvA-DARE (University of Amsterdam) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: National Cancer Institute (P50-CA-69568, R01CA097063, R01 CA97063, P50CA069568)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords: EZH2, Polycomb group proteins, breast cancer aggressiveness, breast cancer progression, cell invasion, anchorage-independent growth, oncogenic transformation, mammary epithelial cells, SET domain, histone deacetylase activity, transcriptional repression, cellular memory, prognostic factors
MeSH terms: Enhancer of Zeste Homolog 2 Protein, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, DNA-Binding Proteins, Epithelial Cells, Female, Humans, Immunohistochemistry, Proteins, RNA, Messenger, Transcription Factors, Polymerase Chain Reaction, Polycomb Repressive Complex 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks